过氧化物酶体增殖物活化受体与非酒精性脂肪性肝病

Peroxisome proliferator-activated receptors and non.alcoholic fatty liver diseases

非酒精性脂肪性肝病（NAFLD）的发病率正在逐年升高,肝脏脂肪沉积是NAFLD的临床病理特征和诊断的金标准.过氧化物酶体增殖物活化受体（PPARs）是配体激活的核受体,在脂代谢、糖代谢和炎性反应中起关键作用,其可作为治疗NAFLD的靶点.PPARs激动剂可减少肝内脂肪沉积,从而逆转NALFD的发展进程,但因其尚存在较多不良反应,所以对PPARs与NAFLD的机制需要进一步研究,从而为PPARs治疗NAFLD提供更有力的证据。

The morbidity of non-alcoholic fatty liver disease （NAFLD） is increasing in recently decades. The hepatic steatosis is the main clinical pathological character and is used as the golden standard for the diagnosis of NAFLD. Peroxisome proliferators-activated receptors （PPARs） are ligand-acfivated nuclear receptors which regulate lipid and glucose metabolism as well as inflammation, and are therefore considered to be a therapeutic target of NAFLD. Studies showed that PPARs agonists reduced fat accumulation in the liver, thus reversing NAFLD progress. However, many side effects are noticed for PPARs agonists in the treatment of NAFLD, more studies are needed to improve our understanding of the roles of PPARs in the progress of NAFLD and find out new evidences for its usage in NAFLD.